{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:01:18Z","timestamp":1781614878642,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Novartis, Santiago, Chile"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40258-025-00972-x","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T13:44:51Z","timestamp":1746539091000},"page":"905-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aggregate Distributional Cost-Effectiveness Analysis of Biologics for the Treatment of Ankylosing Spondylitis in Chile"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-9224","authenticated-orcid":false,"given":"Magdalena","family":"Walbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Jana-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"9570","key":"972_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390.","journal-title":"Lancet"},{"issue":"3","key":"972_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001888","volume":"7","author":"SS Crossfield","year":"2021","unstructured":"Crossfield SS, Marzo-Ortega H, Kingsbury SR, Pujades-Rodriguez M, Conaghan PG. Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. RMD Open. 2021;7(3): e001888.","journal-title":"RMD Open"},{"issue":"5","key":"972_CR3","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/rheumatology\/keab638","volume":"61","author":"D Capelusnik","year":"2022","unstructured":"Capelusnik D, Zhao SS, Boonen A, Ziade N, Medina CL, Dougados M, et al. Individual-level and country-level socio-economic factors and health outcomes in spondyloarthritis: analysis of the ASAS-perSpA study. Rheumatology. 2022;61(5):2043\u201353.","journal-title":"Rheumatology"},{"key":"972_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10067-015-2956-4","volume":"34","author":"N Haroon","year":"2015","unstructured":"Haroon N. Ankylosis in ankylosing spondylitis: current concepts. Clin Rheumatol. 2015;34:1003\u20137.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"972_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/acr.21621","volume":"64","author":"JD Reveille","year":"2012","unstructured":"Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res. 2012;64(6):905\u201310.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"972_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/annrheumdis-2013-204436","volume":"74","author":"F Costantino","year":"2015","unstructured":"Costantino F, Talpin A, Said-Nahal R, Goldberg M, Henny J, Chiocchia G, et al. Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort. Ann Rheum Dis. 2015;74(4):689\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"972_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/acr.21804","volume":"65","author":"G Bakland","year":"2013","unstructured":"Bakland G, Alsing R, Singh K, Nossent JC. Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27. Arthritis Care Res. 2013;65(3):448\u201353.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"972_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2013","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology. 2013;53(4):650\u20137.","journal-title":"Rheumatology"},{"issue":"1","key":"972_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42358-020-00161-5","volume":"61","author":"G Citera","year":"2021","unstructured":"Citera G, Bautista-Molano W, Pel\u00e1ez-Ballestas I, Azevedo VF, Perich RA, M\u00e9ndez-Rodr\u00edguez JA, et al. Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis. Adv Rheumatol. 2021;61(1):2.","journal-title":"Adv Rheumatol."},{"issue":"3","key":"972_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Haibel H, Baraliakos X, Listing J, M\u00e4rker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60(3):717\u201327.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"972_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrrheum.2014.181","volume":"11","author":"A Van Tubergen","year":"2015","unstructured":"Van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nat Rev Rheumatol. 2015;11(2):110\u20138.","journal-title":"Nat Rev Rheumatol"},{"key":"972_CR12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1699-258X(08)76167-9","volume":"4","author":"MA Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez MA, P\u00e9rez C, Saavedra J, Silva F, Fuentealba C, Pozo P, et al. Registro Iberoamericano de Espondiloartritis (RESPONDIA): Chile. Reumatol Cl\u00edn. 2008;4:41\u20137.","journal-title":"Reumatol Cl\u00edn."},{"key":"972_CR13","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1007\/s10067-021-05679-7","volume":"40","author":"MC Hwang","year":"2021","unstructured":"Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clin Rheumatol. 2021;40:3079\u201393.","journal-title":"Clin Rheumatol"},{"issue":"Suppl. 4","key":"972_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/rheumatology\/keaa246","volume":"59","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology. 2020;59(Suppl. 4):47\u201357.","journal-title":"Rheumatology"},{"issue":"2","key":"972_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/annrheumdis-2019-216143","volume":"79","author":"GJ Macfarlane","year":"2020","unstructured":"Macfarlane GJ, Rotariu O, Jones GT, Pathan E, Dean LE. Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). Ann Rheum Dis. 2020;79(2):202\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"972_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000153","volume":"1","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Landew\u00e9 R, van Tubergen A, Boonen A, Stolwijk C, Dougados M, et al. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open. 2015;1(1): e000153.","journal-title":"RMD Open"},{"issue":"4","key":"972_CR17","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/rheumatology\/keab562","volume":"61","author":"S Kumaradev","year":"2022","unstructured":"Kumaradev S, Roux C, Sellam J, Perrot S, Pham T, Dugravot A, et al. Socio-demographic determinants in the evolution of pain in inflammatory rheumatic diseases: results from ESPOIR and DESIR cohorts. Rheumatology. 2022;61(4):1496\u2013509.","journal-title":"Rheumatology"},{"key":"972_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0627-0","volume":"17","author":"S Exarchou","year":"2015","unstructured":"Exarchou S, Lindstr\u00f6m U, Askling J, Eriksson JK, Forsblad-d\u2019Elia H, Neovius M, et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17:1\u20139.","journal-title":"Arthritis Res Ther"},{"key":"972_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jbspin.2020.02.004","volume":"87","author":"SE Ib\u00e1\u00f1ez Vodnizza","year":"2020","unstructured":"Ib\u00e1\u00f1ez Vodnizza SE, Bentumb REV, Valenzuela O, van der Horst-Bruinsma IE. Patients with axial spondyloarthritis report significant differences between men and women and high impact of the disease: large websurvey analysis. Jt Bone Spine. 2020;87:315\u20139.","journal-title":"Jt Bone Spine"},{"issue":"11","key":"972_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/ard.60.11.1033","volume":"60","author":"A Boonen","year":"2001","unstructured":"Boonen A, Chorus A, Miedema H, Van der Heijde D, Landewe R, Schouten H, et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis. 2001;60(11):1033\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"972_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/acr.22730","volume":"68","author":"J Castillo-Ortiz","year":"2016","unstructured":"Castillo-Ortiz J, Ramiro S, Landew\u00e9 R, Van Der Heijde D, Dougados M, Van den Bosch F, et al. Work outcome in patients with ankylosing spondylitis: results from a 12-year followup of an international study. Arthritis Care Res. 2016;68(4):544\u201352.","journal-title":"Arthritis Care Res"},{"issue":"6 Suppl. 28","key":"972_CR22","first-page":"S23","volume":"20","author":"A Boonen","year":"2002","unstructured":"Boonen A. Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol. 2002;20(6 Suppl. 28):S23\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"972_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","volume":"71","author":"HY Chung","year":"2012","unstructured":"Chung HY, Machado P, van Der Heijde D, d\u2019Agostino M-A, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis. 2012;71(6):809\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"972_CR24","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/art.41408","volume":"72","author":"E Nikiphorou","year":"2020","unstructured":"Nikiphorou E, Ramiro S, Sepriano A, Ruyssen-Witrand A, Landew\u00e9 RB, van Der Heijde D. Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five-year data from the DESIR cohort. Arthritis Rheumatol. 2020;72(11):1855\u201362.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"972_CR25","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1053\/berh.2002.0244","volume":"16","author":"A Boonen","year":"2002","unstructured":"Boonen A, Severens JL. Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Rese Clin Rheumatol. 2002;16(4):691\u2013705.","journal-title":"Best Pract Rese Clin Rheumatol."},{"issue":"8","key":"972_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/acr.23468","volume":"70","author":"E Nikiphorou","year":"2018","unstructured":"Nikiphorou E, Ramiro S, Van Der Heijde D, Norton S, Molt\u00f3 A, Dougados M, et al. Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: results from the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. Arthritis Care Res. 2018;70(8):1257\u201362.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"972_CR27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/rheumatology\/ket217","volume":"52","author":"E Haglund","year":"2013","unstructured":"Haglund E, Bremander A, Bergman S, Jacobsson LT, Petersson IF. Work productivity in a population-based cohort of patients with spondyloarthritis. Rheumatology. 2013;52(9):1708\u201314.","journal-title":"Rheumatology"},{"issue":"1","key":"972_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/03009742.2010.487838","volume":"40","author":"EL Healey","year":"2011","unstructured":"Healey EL, Haywood KL, Jordan K, Garratt A, Packham JC. Impact of ankylosing spondylitis on work in patients across the UK. Scand J Rheumatol. 2011;40(1):34\u201340.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"972_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/ard.2009.116764","volume":"69","author":"A Boonen","year":"2010","unstructured":"Boonen A, Brinkhuizen T, Landew\u00e9 R, van der Heijde D, Severens JL. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis. 2010;69(6):1123\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"972_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/ard.61.5.429","volume":"61","author":"A Boonen","year":"2002","unstructured":"Boonen A, van der Heijde D, Landew\u00e9 R, Spoorenberg A, Schouten H, Rutten-van M\u00f6lken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002;61(5):429\u201337.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"972_CR31","first-page":"571","volume":"35","author":"S Espahbodi","year":"2017","unstructured":"Espahbodi S, Bassett P, Cavill C, Freeth M, Hole J, Sengupta R. Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. Clin Exp Rheumatol. 2017;35(4):571\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"972_CR32","unstructured":"Ministerio de Salud de Chile. Informe de evaluaci\u00f3n cient\u00edfica basada en la evidencia disponible. Espondilitis Anquilosante. 1era Edici\u00f3n 2017. Retrieved December 2024 from: www.minsal.cl."},{"issue":"4","key":"972_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003468","volume":"9","author":"M Rudwaleit","year":"2023","unstructured":"Rudwaleit M, M\u00f8rup MF, Humphries B, Zannat NE, Willems D, Taieb V, et al. Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. RMD Open. 2023;9(4): e003468.","journal-title":"RMD Open"},{"issue":"9","key":"972_CR34","first-page":"A937","volume":"20","author":"R Rojas","year":"2017","unstructured":"Rojas R, Barbeau M, Jugl S, MacPherson A. Secukinumab shows higher symptomatic improvement and lower cost per response vs. adalimumab after one year treatment of active ankylosing spondylitis: a cost per responder analysis from a Chilean perspective. Value Health. 2017;20(9):A937.","journal-title":"Value Health."},{"issue":"3","key":"972_CR35","doi-asserted-by":"publisher","first-page":"A46","DOI":"10.1016\/j.jval.2014.03.278","volume":"17","author":"M Bonafede","year":"2014","unstructured":"Bonafede M, Johnson B, Princic N, Shah N, Harrison D. Cost-effectiveness of Ra biologics in the two years following initiation using a validated claims-based algorithm in a United States commercially insured population. Value Health. 2014;17(3):A46\u20137.","journal-title":"Value Health."},{"issue":"9","key":"972_CR36","doi-asserted-by":"publisher","first-page":"A938","DOI":"10.1016\/j.jval.2017.08.2980","volume":"20","author":"MR Prada","year":"2017","unstructured":"Prada MR, Cardenas NR, Serrano G, Huerfano L. Cost-utility analysis of secukinumab use versus TNF-\u03b1 inhibitors, in patients with ankylosing spondilytis. Value Health. 2017;20(9):A938\u20139.","journal-title":"Value Health."},{"issue":"1","key":"972_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10\u201331.","journal-title":"Value Health."},{"issue":"2","key":"972_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","volume":"20","author":"R Cookson","year":"2017","unstructured":"Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, et al. Using cost-effectiveness analysis to address health equity concerns. Value Health. 2017;20(2):206\u201312.","journal-title":"Value Health."},{"issue":"5","key":"972_CR39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jval.2019.03.006","volume":"22","author":"J Love-Koh","year":"2019","unstructured":"Love-Koh J, Cookson R, Gutacker N, Patton T, Griffin S. Aggregate distributional cost-effectiveness analysis of health technologies. Value Health. 2019;22(5):518\u201326.","journal-title":"Value Health."},{"issue":"3","key":"972_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/0272989X19829726","volume":"39","author":"S Griffin","year":"2019","unstructured":"Griffin S, Love-Koh J, Pennington B, Owen L. Evaluation of intervention impact on health inequality for resource allocation. Med Decis Mak. 2019;39(3):171\u201382.","journal-title":"Med Decis Mak"},{"issue":"1","key":"972_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12939-023-01972-w","volume":"22","author":"MA Espinoza","year":"2023","unstructured":"Espinoza MA, Severino R, Balmaceda C, Abbott T, Cabieses B. The socioeconomic distribution of life expectancy and healthy life expectancy in Chile. Int J Equity Health. 2023;22(1):160.","journal-title":"Int J Equity Health."},{"key":"972_CR42","unstructured":"Superintendencia de Salud de Chile. \u00bfC\u00f3mo se clasifican los beneficiarios de FONASA seg\u00fan su tramo? 2022. Retrieved December 2024 from https:\/\/www.superdesalud.gob.cl\/consultas\/667\/w3-printer-6304.html."},{"issue":"2","key":"972_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/0272989X20904360","volume":"40","author":"J Love-Koh","year":"2020","unstructured":"Love-Koh J, Cookson R, Claxton K, Griffin S. Estimating social variation in the health effects of changes in health care expenditure. Med Decis Making. 2020;40(2):170\u201382.","journal-title":"Med Decis Making"},{"key":"972_CR44","unstructured":"Ministerio de Salud de Chile. Gu\u00eda Metodol\u00f3gica para la evaluaci\u00f3n econ\u00f3mica de intervenciones en salud en Chile. 2013. Retrieved December 2024 from: https:\/\/www.minsal.cl\/etesa-publicaciones\/."},{"issue":"10","key":"972_CR45","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/hec.3430","volume":"26","author":"M Robson","year":"2017","unstructured":"Robson M, Asaria M, Cookson R, Tsuchiya A, Ali S. Eliciting the level of health inequality aversion in England. Health Econ. 2017;26(10):1328\u201334.","journal-title":"Health Econ"},{"key":"972_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113573","volume":"269","author":"S McNamara","year":"2021","unstructured":"McNamara S, Tsuchiya A, Holmes J. Does the UK-public\u2019s aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment. Soc Sci Med. 2021;269: 113573.","journal-title":"Soc Sci Med"},{"key":"972_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2024.117248","volume":"370","author":"S McNamara","year":"2025","unstructured":"McNamara S, Tsuchiya A, Holmes J. Corrigendum to \u2018Does the UK-public\u2019s aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment\u2019 [Soc. Sci. Med. Volume 269, January 2021, 113573]. Soci Sci Med. 2025;370: 117248.","journal-title":"Soci Sci Med."},{"issue":"8","key":"972_CR48","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40273-023-01281-8","volume":"41","author":"A Meunier","year":"2023","unstructured":"Meunier A, Longworth L, Gomes M, Ramagopalan S, Garrison LP, Popat S. Distributional cost-effectiveness analysis of treatments for non-small cell lung cancer: an illustration of an aggregate analysis and its key drivers. Pharmacoeconomics. 2023;41(8):1011\u201325.","journal-title":"Pharmacoeconomics"},{"key":"972_CR49","volume-title":"Distributional cost-effectiveness analysis: quantifying health equity impacts and trade-offs","year":"2020","unstructured":"Cookson R, Griffin S, Norheim OF, Culyer AJ, editors. Distributional cost-effectiveness analysis: quantifying health equity impacts and trade-offs. Oxford: Oxford University Press; 2020."},{"issue":"1","key":"972_CR50","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/ijerph20010505","volume":"20","author":"D Steijger","year":"2022","unstructured":"Steijger D, Chatterjee C, Groot W, Pavlova M. Challenges and limitations in distributional cost-effectiveness analysis: a systematic literature review. Int J Environ Res Public Health. 2022;20(1):505.","journal-title":"Int J Environ Res Public Health"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00972-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-025-00972-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00972-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:24:29Z","timestamp":1757168669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-025-00972-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1007\/s40258-025-00972-x","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"22 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Novartis, Santiago, Chile through FourResearch Limited. The authors conducted this study within the framework of their consultancy work with FourResearch Limited and did not receive any additional incentives for this study. The funder had no involvement in the research design, data collection, analysis, interpretation, manuscript preparation or the decision to submit for publication. Employees from the company provided helpful comments related to the format on an earlier version of the manuscript. The views expressed in this paper are those of the authors and not necessarily those of the funders.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Magdalena Walbaum and Nicolas Jana-Valencia have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The cost-effectiveness report can be accessed upon request to the corresponding author. All other data used to support the findings of this study are included within the article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The code is available upon request and subject to the authors\u2019 authorisation.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Both authors contributed to the study concept and design, acquisition of data, analysis and interpretation of data, and drafting and editing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}